- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01089153
Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research
September 6, 2011 updated by: Randall Wolcott, Southwest Regional Wound Care Center
Current spirochaete infection identification and diagnostic strategies have important limitations.
Recent development may allow for an improvement in diagnostic, screening and survey capabilities.
The goal of this study is to evaluate blood, urine and fecal samples from a variety of sources and generate information on the occurrence and epidemiology of spirochetes in the general and at risk populations.
Study Overview
Status
Completed
Detailed Description
The intent of this protocol is to obtain blood, feces and urine samples from subjects with or without a suspected spirochaete infection, so these samples can be used in spirochaete-related scientific studies.
Study Type
Observational
Enrollment (Actual)
35
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Blood, feces and urine samples may be collected from subjects with known or suspected spirochetal disease or from subjects not suspected to be infected with spirochetes
Description
Inclusion Criteria:
- The subject must be able to be fully consented to the study.
- The subject must be 18 years of age or older.
- The subject must be mentally competent as determined by the Investigator.
Exclusion Criteria:
- The subject must not be currently incarcerated or pregnant.
- The subject must not weigh less than 110lbs.
- If the subject will be contributing more that 60 ml of blood during an 8 (eight) week period, then the subject must not have donated red blood cells within the last 8 (eight) weeks.
- If the Subject's health would be compromised by contributing up to 30ml of peripheral blood.
- If in the opinion of the Investigator, the subject has any clinically significant medical diagnosis/conditions which would prevent participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (ACTUAL)
December 1, 2010
Study Completion (ACTUAL)
December 1, 2010
Study Registration Dates
First Submitted
March 16, 2010
First Submitted That Met QC Criteria
March 16, 2010
First Posted (ESTIMATE)
March 18, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 7, 2011
Last Update Submitted That Met QC Criteria
September 6, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 56-RW-015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on The Samples Will be Studied in Order to Attempt to Better Understand the Occurrence of Blood, Feces and Urine Borne Spirochaetes
-
University Of PerugiaUnknownThe Primary Study Objective is to Assess the Efficacy and | Safety of Extended 4-week Heparin Prophylaxis Compared to | Prophylaxis Given for 8±2 Days After Planned Laparoscopic | Surgery for Colorectal Cancer. | The Clinical Benefit Will be Evaluated as the Difference in | the Incidence of... and other conditionsItaly